209 related articles for article (PubMed ID: 29128384)
1. Adverse effects of single-component measles vaccine in school children.
Tosun S; Olut AI; Tansug N
Vaccine; 2017 Dec; 35(52):7309-7311. PubMed ID: 29128384
[TBL] [Abstract][Full Text] [Related]
2. [Safety and immunogenicity of measles attenuated live vaccine prepared by master seed lot vaccine of Shanghai-191 strain].
Zhang SJ; Xiao QY; Li FJ
Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):423-5. PubMed ID: 20084967
[TBL] [Abstract][Full Text] [Related]
3. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
4. Determinants of low measles vaccination coverage in children living in an endemic area.
Lo Vecchio A; Cambriglia MD; Fedele MC; Basile FW; Chiatto F; Miraglia Del Giudice M; Guarino A
Eur J Pediatr; 2019 Feb; 178(2):243-251. PubMed ID: 30430239
[TBL] [Abstract][Full Text] [Related]
5. Role of schools in the transmission of measles in rural Senegal: implications for measles control in developing countries.
Cisse B; Aaby P; Simondon F; Samb B; Soumaré M; Whittle H
Am J Epidemiol; 1999 Feb; 149(4):295-301. PubMed ID: 10025469
[TBL] [Abstract][Full Text] [Related]
6. First 5 years of measles elimination in southern Africa: 1996-2000.
Biellik R; Madema S; Taole A; Kutsulukuta A; Allies E; Eggers R; Ngcobo N; Nxumalo M; Shearley A; Mabuzane E; Kufa E; Okwo-Bele JM
Lancet; 2002 May; 359(9317):1564-8. PubMed ID: 12047966
[TBL] [Abstract][Full Text] [Related]
7. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
8. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
[TBL] [Abstract][Full Text] [Related]
10. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 Months During a Measles Outbreak in The Netherlands in 2013-2014.
van der Maas NA; Woudenberg T; Hahné SJ; de Melker HE
J Infect Dis; 2016 May; 213(9):1466-71. PubMed ID: 26690343
[TBL] [Abstract][Full Text] [Related]
12. [Epidemiological investigations on measles in unvaccinated and vaccinated children (author's transl)].
Wiedermann G; Ambrosch F
Wien Klin Wochenschr; 1976 Sep; 88(17):545-54. PubMed ID: 997537
[TBL] [Abstract][Full Text] [Related]
13. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign.
D'Souza RM; Campbell-Lloyd S; Isaacs D; Gold M; Burgess M; Turnbull F; O'Brien E
Commun Dis Intell; 2000 Feb; 24(2):27-33. PubMed ID: 10758692
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka.
Wijesinghe PR; Abeysinghe MR; Yoksan S; Yao Y; Zhou B; Zhang L; Yaich M; Neuzil KM; Victor JC
Vaccine; 2014 Aug; 32(37):4751-7. PubMed ID: 24951871
[TBL] [Abstract][Full Text] [Related]
15. [Reactions after MMR vaccination].
Kaaber K; Samuelsson IS; Larsen SO
Ugeskr Laeger; 1990 Jun; 152(23):1672-6. PubMed ID: 2363211
[TBL] [Abstract][Full Text] [Related]
16. Will the current measles vaccines ever eradicate measles?
Stephenson J
Expert Rev Vaccines; 2002 Oct; 1(3):355-62. PubMed ID: 12901574
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
[TBL] [Abstract][Full Text] [Related]
18. Measles vaccination: new strategies and formulations.
de Vries RD; Stittelaar KJ; Osterhaus AD; de Swart RL
Expert Rev Vaccines; 2008 Oct; 7(8):1215-23. PubMed ID: 18844595
[TBL] [Abstract][Full Text] [Related]
19. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
20. Booster vaccination with further live attenuated measles vaccine.
Bass JW; Halstead SB; Fischer GW; Podgore JK; Pearl WR; Schydlower M; Wiebe RA; Ching FM
JAMA; 1976 Jan; 235(1):31-4. PubMed ID: 945997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
